Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Liabilities and Shareholders Equity (2018 - 2025)

Historic Liabilities and Shareholders Equity for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $764.0 million.

  • Bicycle Therapeutics' Liabilities and Shareholders Equity fell 2335.52% to $764.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 billion, marking a year-over-year increase of 751.78%. This contributed to the annual value of $956.9 million for FY2024, which is 6072.52% up from last year.
  • Bicycle Therapeutics' Liabilities and Shareholders Equity amounted to $764.0 million in Q3 2025, which was down 2335.52% from $832.2 million recorded in Q2 2025.
  • Over the past 5 years, Bicycle Therapeutics' Liabilities and Shareholders Equity peaked at $1.1 billion during Q2 2024, and registered a low of $223.8 million during Q1 2021.
  • In the last 5 years, Bicycle Therapeutics' Liabilities and Shareholders Equity had a median value of $479.8 million in 2021 and averaged $584.2 million.
  • Per our database at Business Quant, Bicycle Therapeutics' Liabilities and Shareholders Equity skyrocketed by 19772.64% in 2021 and then crashed by 2335.52% in 2025.
  • Quarter analysis of 5 years shows Bicycle Therapeutics' Liabilities and Shareholders Equity stood at $479.8 million in 2021, then decreased by 14.42% to $410.6 million in 2022, then surged by 44.99% to $595.3 million in 2023, then skyrocketed by 60.73% to $956.9 million in 2024, then fell by 20.16% to $764.0 million in 2025.
  • Its last three reported values are $764.0 million in Q3 2025, $832.2 million for Q2 2025, and $883.9 million during Q1 2025.